Evidence map›Paper›PMID 41249043›Full record

ArticleThe Kobe journal of medical sciences2025

284 nm UVB Phototherapy Regulates Immunoinflammatory Responses and Improves Atherosclerotic Plaque Stability in Mice.

Ken Ito, Naoto Sasaki, Aga Krisnanda, Toru Tanaka, Sayo Horibe, Motoaki Iwaya, Atsushi Fukunaga, Yoshiyuki Rikitake

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kobe journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ken ItoLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Naoto SasakiLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Aga KrisnandaLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Toru TanakaLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Sayo HoribeLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Motoaki IwayaDepartment of Materials Science and Engineering, Meijo University, Nagoya, Japan.
Atsushi FukunagaDepartment of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yoshiyuki RikitakeLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.

Funding

JSPS KAKENHI JP24K11301
6 · The paper itself

Abstract

aimWe previously reported that broad-band and specific wavelengths of ultraviolet B (UVB) limit the development of atherosclerosis by augmenting anti-inflammatory immune responses in hypercholesterolemic mice. This study aimed to elucidate the effect of 284 nm UVB on the stabilization of atherosclerotic plaques and the underlying mechanisms. METHODS AND

resultsSix- to eight-week-old male LDL receptor-deficient (

conclusions284 nm UVB irradiation in combination with lipid-lowering therapy improves the stability of atherosclerotic plaques by augmenting anti-inflammatory Treg immune responses. The combination of aggressive lipid-lowering therapies and 284 nm UVB phototherapy may serve as an attractive therapeutic approach for high-risk patients with vulnerable atherosclerotic plaques.

Indexed as

AtherosclerosisInflammationPlaque, AtheroscleroticUltraviolet TherapyAnimalsDiet, High-FatMaleMiceMice, Inbred C57BLMice, KnockoutReceptors, LDLT-Lymphocytes, RegulatoryUltraviolet RaysReceptors, LDLAtherosclerosisInflammationPlaque stabilizationT cellsUltraviolet B

Identifiers

PMID41249043
PMCPMC13095045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.